AtriCure (ATRC) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed STAAR Surgical (STAA) over the past year, gaining 56.2% versus a loss of 16.3%. Over five years, ATRC leads with a -25.3% price change compared with -80.5% for STAA. AtriCure is the larger company by market cap ($2.71 billion vs $1.12 billion), about 2.4 times the size.
On valuation, STAAR Surgical trades at a lower forward P/E (20.1x vs 122.8x for AtriCure).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | STAA |
|---|---|---|
| Share price | $53.31 | $22.36 |
| Market cap | $2.71B | $1.12B |
| 1-day change | -0.69% | +0.95% |
| YTD return | +34.76% | -3.16% |
| 1-year return | +56.24% | -16.32% |
| 5-year return | -25.30% | -80.54% |
| P/E ratio (TTM) | 253.86 | 279.50 |
| Forward P/E | 122.84 | 20.12 |
| EPS (TTM) | $0.21 | $0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | — |
| Revenue growth (YoY) | +14.88% | — |
| Net income (latest FY) | $-11.45M | — |
| Gross margin | 74.98% | — |
| Operating margin | -1.77% | — |
| Net margin | -2.14% | — |
| 52-week high | $61.70 | $35.87 |
| 52-week low | $25.36 | $15.59 |
| Distance from 52-week high | -13.60% | -37.66% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +2.96% | +25.22% |
| Average volume | 1.10M | 1.00M |
| Shares outstanding | 50.87M | 50.14M |
| Employees | 1,350 | 921 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AtriCure is about 2.4 times larger than STAAR Surgical by market value ($2.71B vs $1.12B).
- ATRC has outperformed STAA by 72.6 percentage points over the past year.
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
ATRC vs STAA FAQ
Which is bigger, AtriCure or STAAR Surgical?
AtriCure (ATRC) is larger, with a market capitalization of $2.71B compared with $1.12B for STAAR Surgical (STAA).
Which stock has performed better over the past year, ATRC or STAA?
ATRC returned +56.24% over the past 12 months, compared with -16.32% for STAA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATRC or STAA?
ATRC has the lower trailing P/E at 253.9, versus 279.5 for STAA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are AtriCure and STAAR Surgical in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for AtriCure and Ophthalmic Goods for STAAR Surgical.